-

The Dark Intelligence Group: Clinical Laboratories Have New Resource to Assist with COVID-19 Testing and Help Restore Cash Flow to Pre-Pandemic Levels

AUSTIN, Texas--(BUSINESS WIRE)--Even as federal and state officials promise greater numbers of COVID-19 lab tests, the nation’s clinical laboratories, pathology practices and hospitals struggle to deliver those greater numbers of tests. To help labs get the answers they so desperately need, The Dark Intelligence Group (TDIG) announces the launch of the COVID-19 STAT Intelligence Briefings Service.

During this disruptive SARS-CoV-2 pandemic, TDIG has created this free intelligence service with a total focus on COVID-19 and everything labs need to meet the business challenges of the pandemic, including:

  • Latest on rapid molecular serology COVID-19 testing, with sources and supply chain updates
  • How labs are getting paid for COVID-19 by Medicare, Medicaid, and private health plans
  • Daily updates on changes to federal regulations and directives from the FDA, CDC, and CMS, and much more

“Since early March, routine specimen volumes and cash flow have declined by 60% or more at medical labs,” stated Robert L. Michel, President and Founder of TDIG. “This new service provides valuable tools, resources, and data to not only help labs with their COVID-19 testing, but also to give them actionable steps to swiftly restore their cash flow to pre-pandemic levels.”

COVID-19 STAT Intelligence Briefings service updates daily. It includes briefings, interviews with leading subject matter experts, podcasts and webinars, plus timely analysis of the daily changes in the pandemic. It is all actionable information, supplemented with real-time national lab test dashboards fed with data from TDIG partners at XIFIN, Visiun, and hc1.com.

COVID-19 STAT Intelligence Briefings is also introducing twice-weekly conference calls, so attendees can hear updates from nationally known thought leaders and get critical questions answered on managing their laboratories during the SARS-CoV-2 outbreak.

Contacts

Bob Croce
bcroce@darkreport.com

Industry:

The Dark Intelligence Group

Release Summary
Clinical Laboratories Have New Resource to Assist with COVID-19 Testing and Help Restore Cash Flow to Pre-Pandemic Levels
Release Versions
English

Contacts

Bob Croce
bcroce@darkreport.com

More News From The Dark Intelligence Group

LabX Media Group Acquires The Dark Intelligence Group Inc, including The Dark Report and the Executive War College

AUSTIN, Texas--(BUSINESS WIRE)--The Dark Intelligence Group (TDIG) announced today that it has sold all its information services assets to LabX Media Group of Midland, Ontario, Canada. This sale involves all TDIG products and services, such as The Dark Report intelligence service, DarkDaily ebriefings, webinars, reports, and events, including the Executive War College on Diagnostic, Laboratory, and Pathology Management, the largest global conference on laboratory management for senior laborator...

Operationalizing FDA LDT Compliance: Expert Panel Reveals Essential Strategies and Actions for Meeting the 1st Reporting Milestone

AUSTIN, Texas--(BUSINESS WIRE)--Many clinical laboratories are now under the gun to achieve Phase One compliance with the Food and Drug Administration’s (FDA) LDT rule before the May 2025 deadline. Labs performing LDTs must take immediate action to protect their most important LDTs that improve patient care while generating substantial reimbursement. This is a high stakes situation for labs offering LDTs because they have only five months to secure their most valuable LDTs. To help labs underst...

Experts to Identify Essential Steps & Pitfalls to Help Clinical Laboratories Meet the Deadline to Comply with the FDA’s Laboratory Developed Test (LDT) Rule

AUSTIN, Texas--(BUSINESS WIRE)--With the first important deadline for compliance with the Food and Drug Administration’s (FDA) LDT rule only eight months away, experts urge clinical laboratories performing LDTs to take immediate action. This is essential to protect their most important LDTs that improve patient care while generating substantial reimbursement. The FDA’s final rule on Laboratory Developed Tests (LDTs) ushers in a radical overhaul of the FDA’s longstanding policy of enforcement di...
Back to Newsroom